OrthoPediatrics Corp. (NASDAQ:KIDS) Stake Boosted by Invesco Ltd.

Invesco Ltd. grew its stake in shares of OrthoPediatrics Corp. (NASDAQ:KIDS) by 3.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 16,363 shares of the company’s stock after purchasing an additional 469 shares during the quarter. Invesco Ltd. owned approximately 0.07% of OrthoPediatrics worth $379,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in the stock. Wellington Management Group LLP raised its stake in shares of OrthoPediatrics by 20.2% during the fourth quarter. Wellington Management Group LLP now owns 1,061,299 shares of the company’s stock valued at $24,601,000 after purchasing an additional 178,078 shares in the last quarter. Mutual of America Capital Management LLC raised its stake in OrthoPediatrics by 57.1% during the 4th quarter. Mutual of America Capital Management LLC now owns 169,021 shares of the company’s stock valued at $3,918,000 after purchasing an additional 61,412 shares during the period. JPMorgan Chase & Co. grew its stake in OrthoPediatrics by 204.8% during the 4th quarter. JPMorgan Chase & Co. now owns 42,817 shares of the company’s stock valued at $992,000 after acquiring an additional 28,768 shares in the last quarter. EntryPoint Capital LLC acquired a new position in OrthoPediatrics in the 4th quarter valued at approximately $528,000. Finally, Triodos Investment Management BV raised its holdings in shares of OrthoPediatrics by 29.2% during the fourth quarter. Triodos Investment Management BV now owns 93,000 shares of the company’s stock worth $2,156,000 after acquiring an additional 21,000 shares in the last quarter. 69.05% of the stock is currently owned by institutional investors.

OrthoPediatrics Stock Performance

NASDAQ:KIDS opened at $21.40 on Friday. The company has a current ratio of 7.17, a quick ratio of 3.68 and a debt-to-equity ratio of 0.19. The stock has a market capitalization of $519.74 million, a P/E ratio of -17.40 and a beta of 1.09. The firm has a 50 day moving average of $23.18 and a 200-day moving average of $24.24. OrthoPediatrics Corp. has a 1 year low of $20.25 and a 1 year high of $35.99.

OrthoPediatrics (NASDAQ:KIDS) last issued its quarterly earnings results on Tuesday, March 4th. The company reported ($0.29) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.04. The business had revenue of $52.67 million during the quarter, compared to analyst estimates of $51.16 million. OrthoPediatrics had a negative net margin of 15.00% and a negative return on equity of 5.78%. During the same quarter last year, the business posted ($0.23) earnings per share. As a group, sell-side analysts anticipate that OrthoPediatrics Corp. will post -0.93 EPS for the current fiscal year.

Insider Activity

In other OrthoPediatrics news, General Counsel Daniel J. Gerritzen sold 5,310 shares of the company’s stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $24.86, for a total transaction of $132,006.60. Following the completion of the sale, the general counsel now owns 110,767 shares in the company, valued at approximately $2,753,667.62. The trade was a 4.57 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO David R. Bailey sold 6,620 shares of the firm’s stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $24.86, for a total value of $164,573.20. Following the completion of the transaction, the chief executive officer now owns 319,155 shares in the company, valued at $7,934,193.30. This represents a 2.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 23,732 shares of company stock valued at $589,978. 32.70% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several research firms have commented on KIDS. Lake Street Capital initiated coverage on shares of OrthoPediatrics in a research report on Monday, April 7th. They issued a “buy” rating and a $37.00 target price for the company. Stifel Nicolaus reduced their price objective on OrthoPediatrics from $40.00 to $32.00 and set a “buy” rating for the company in a research report on Wednesday, March 5th. Truist Financial lowered their price target on OrthoPediatrics from $26.00 to $24.00 and set a “hold” rating on the stock in a research note on Friday, April 11th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $42.00 price objective on shares of OrthoPediatrics in a report on Wednesday, April 9th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $37.00.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.